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195REVIEWTargeting mediators of Wnt signalling pathways by GnRH
in gonadotropesSamantha Gardner, Emmanouil Stavrou, Patricia E Rischitor, Elena Faccenda
and Adam J Pawson
Medical Research Council Human Reproductive Sciences Unit, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, Scotland, UK
(Correspondence should be addressed to A J Pawson; Email: a.pawson@hrsu.mrc.ac.uk)
(S Gardner is now at Department of Biochemistry and Molecular Biology, Oregon Health and Sciences University, Portland, Oregon 97239-3098, USA)AbstractThe binding of GnRH to its receptor on pituitary gonadotropes leads to the targeting of a diverse array of signalling
mediators. These mediators drive multiple signal transduction pathways, which in turn regulate a variety of cellular
processes, including the biosynthesis and secretion of the gonadotropins LH and FSH. Advances in our understanding
of the mechanisms and signalling pathways that are recruited to regulate gonadotrope function are continually being
made. This review will focus on the recent demonstration that key mediators of the canonical Wnt signalling pathway are
targeted by GnRH in gonadotropes, and that these may play essential roles in regulating the expression of many of the
key players in gonadotrope biology, including the GnRH receptor and the gonadotropins.Journal of Molecular Endocrinology (2010) 44, 195–201Introduction
GnRH occupancy of GnRH receptors leads to the
activation of multiple signal transduction pathways
(Naor 1997, 2009, Naor et al. 2000, Millar et al. 2004,
2008, Caunt et al. 2006, Dobkin-Bekman et al. 2006). In
gonadotropes, GnRH activates phospholipase-Cb via
coupling to Gq/11, resulting in the hydrolysis of
membrane-boundphosphatidylinositol 4,5-bisphosphate
into inositol 1,4,5-triphosphate and diacylglycerol, which
respectively mobilise intracellular Ca2C and activate
protein kinase C (PKC). The diverse mechanisms and
intracellular signalling pathways that have been reported
to contribute to the regulation of gonadotrope function
in response to GnRH stimulation have been reviewed
extensively (Millar et al. 2004, 2008, Pawson & McNeilly
2005, Naor 2009), and will not be discussed further here.
Instead, this review will focus on the proposed roles of
Wnt signalling mediators in regulating gonadotrope
function in response to GnRH.A ‘rough guide’ to Wnt signalling
Wnt signalling plays an important role in embryonic
development influencing cell proliferation, survivalJournal of Molecular Endocrinology (2010) 44, 195–201
0952–5041/10/044–195 q 2010 Society for Endocrinology Printed in Great Britainand differentiation (Huelsken & Behrens 2002, van Es
et al. 2003, Moon et al. 2004, Nelson & Nusse 2004).
Aberrant Wnt signalling can lead to a range of diseases,
most notably cancer (Polakis 2000). The canonical
Wnt/b-catenin pathway is perhaps the best described
Wnt signalling pathway. The key effector of this pathway
is b-catenin. In the absence of Wnt ligand (19 family
members in humans) stimulation of the Frizzled (FZD)
family of receptors (10 family members in humans),
cellular b-catenin levels are kept very low. This is
because b-catenin is held in a destruction complex,
which includes amongst others adenomatous polyposis
coli, axin, glycogen synthase kinase 3 (GSK3) and
casein kinase 1 (CK1). GSK3 hyperphosphorylates
b-catenin, thereby targeting it for ubiquitination and
subsequent degradation via the proteasomal
degradation pathway. When Wnts bind to and activate
the FZD receptors, GSK3 activity is inhibited, allowing
the levels of b-catenin to stabilise, and b-catenin
translocates to the nucleus where it acts as a co-factor
to T cell factor (TCF)/lymphoid enhancer factor
transcription factors to promote the transcription of
Wnt target genes, many of which are key in develop-
mental processes (Huelsken & Behrens 2002, van Es
et al. 2003, Moon et al. 2004).DOI: 10.1677/JME-09-0168
Online version via http://www.endocrinology-journals.org
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cal Wnt pathways, several of which have been proposed
over the past 20 years, including theWnt/Ca2C pathway
and Wnt/c-Jun N-terminal kinase (JNK) pathway (Kuhl
et al. 2000, van Es et al. 2003, Veeman et al. 2003, Kohn &
Moon 2005). These pathways are also activated by Wnt
ligands binding to FZD receptors, and are thought to
influence processes such as cell polarity, cytoskeletal
reorganisation and cell movement, and utilise a diverse
array of signalling mediators and transcription factors
to drive these events, including PKC, Ca2C/calmodulin
(CaM), calcineurin (CaN), Ca2C/CaM-dependent
kinase II, nuclear factor of activated T cells (NFAT),
dishevelled, RhoA, Rac, Cdc42 and JNK (Kuhl et al.
2000, van Es et al. 2003, Veeman et al. 2003, Kohn &
Moon 2005, Katoh & Katoh 2007).
Although there are two isoforms (a and b) of GSK3, it
is GSK3b that phosphorylates b-catenin, and targets
it for ubiquitination and proteolytic degradation in the
inactive canonical Wnt/b-catenin signalling pathway
(Frame & Cohen 2001). Following activation of
Wnt/b-catenin signalling, GSK3b is inhibited by a
poorly defined mechanism, thereby allowing the
stabilisation and accumulation of b-catenin levels.
GSK3 was originally identified as a key mediator of
insulin signalling, and is now thought to be involved in
many other signalling pathways with a diverse array of
proposed substrates, including Tau, CREB, NFkB,
MUC1, cyclin D1, MYC, NFAT and JUN (Frame &
Cohen 2001, Grimes & Jope 2001). Multiple kinases
have been implicated in the Ser9 and Ser21 phospho-
inhibition of GSK3b and GSK3a respectively, including
the phosphatidylinositol 3-kinase (PI3K)–Akt/protein
kinase B (PKB) signalling axis (such as that occurring in
classical insulin signalling), p90RSK, PKC, protein
kinase A (PKA), p70 S6 kinase and extracellular
signal-regulated protein kinase (ERK) (Stambolic &
Woodgett 1994, Frame & Cohen 2001, Grimes & Jope
2001, Ding et al. 2005). It was initially thought that Ser9
GSK3b phospho-inhibition was the mechanism of
GSK3b inhibition within the Wnt/b-catenin pathway
(Frame & Cohen 2001). However, a study using a mouse
knock-in of a Ser9Ala GSK3bmutation reported normal
embryonic development, suggesting that the Ser9
phospho-inhibition of GSK3b is not implicated in
canonical Wnt signalling (McManus et al. 2005). Both
isoforms of GSK3 are probably important for Wnt
signalling because deletion of one has no effect, as long
as the other is present, possibly suggesting isoform
redundancy (Doble & Woodgett 2003). Furthermore,
in the mouse knock-in analysis where the Ser9/21
residues of GSK3b/a respectively were mutated to
alanine residues, normal b-catenin accumulation was
observed in response to Wnt3a stimulation, again
confirming that Ser9 phosphorylation is not the
mechanism for inhibiting GSK3b in Wnt/b-cateninJournal of Molecular Endocrinology (2010) 44, 195–201signalling (McManus et al. 2005). In addition,
mutational studies of the ‘insulin pool’ of GSK3 suggest
that insulin-induced Ser9/21 phospho-inhibition is not
involved in the activation of the Wnt signalling pathway,
and that Wnt signalling does not alter the glycogen
synthase output of insulin signalling (Ding et al. 2000,
Ng et al. 2009). The ‘insulin’ and Wnt pools of GSK3b
may therefore be considered to be functionally distinct.
A number of theories have arisen regarding
the mechanism involved in GSK3b inhibition in the
Wnt/b-catenin pathway. Some involve the GSK3b-
binding protein called frequently rearranged in
advanced T-cell lymphoma (FRAT), which can block
GSK3-induced phosphorylation of b-catenin without
affecting glycogen synthase activity in the insulin
signalling pathway (Thomas et al. 1999). Other theories
involve the essential Wnt pathway protein dishevelled
(Huelsken & Behrens 2002, van Es et al. 2003, Moon
et al. 2004). It has also been demonstrated that Wnt
signalling inhibits GSK3 through a PKC-mediated
mechanism (Cook et al. 1996), suggesting that PKC
may have a role in inhibiting GSK3 within the canonical
Wnt/b-catenin pathway, in addition to the phospho-
inhibition at Ser9/21 such as in classical insulin
signalling. CK1 can enhance GSK3 activity by acting as
a priming kinase. However, CK1 also has an essential
role in positively transducing the canonical Wnt signal,
suggesting its involvement in GSK3b inhibition (Doble
&Woodgett 2003). Alternatively, different CK1 isoforms
may positively and negatively regulate GSK3b activity.
Interestingly, GSK3b not only has been implicated in
canonical Wnt/b-catenin signalling, but may also play
a negative regulatory role in the non-canonical
Wnt/Ca2C pathway, in which it is thought to function
as a nuclear export kinase, thus terminating NFAT
transcriptional activity (Crabtree & Olson 2002, van Es
et al. 2003, Katoh & Katoh 2007).
The FZD family of receptors are seven-trans-
membrane-spanning receptors that resemble G protein
coupled receptor (GPCRs), and are now listed by the
International Union of Pharmacology as a novel and
separate family of GPCRs, the ‘Class FZD’ (Schulte &
Bryja 2007). One of the first demonstrations that FZDs
signal via G-protein coupling came from the early
studies by Malbon et al. (Liu et al. 1999, 2001). It was
demonstrated that b2-adrenergic receptor/FZD1 chi-
mera bearing the cytoplasmic domains of rat FZD1 was
able to stimulate b-catenin stabilisation and b-catenin/
TCF transcriptional activity in response to isoprenaline
stimulation, and that this was inhibited when certain
a-protein a-subunits (Gao and Gaq) were depleted by
antisense RNA, or by pertussis toxin pretreatment (Liu
et al. 1999, 2001). Importantly, these and subsequent
studies appeared to suggest that non-FZD GPCRs could
target b-catenin activity in response to stimulation by
their cognate ligands (Malbon 2005).www.endocrinology-journals.org
Figure 1 Targeting Wnt signalling mediators by GnRH
in gonadotropes. GnRH activates PLC-b via coupling to Gq/11,
resulting in the hydrolysis of membrane-bound phosphatidyl-
inositol 4,5-bisphosphate into inositol 1,4,5-triphosphate (InsP3)
and diacylglycerol (DAG), which respectively mobilise intracellular
Ca2C and activate protein kinase C (PKC). GnRH targets
Ser9 phospho-inhibition of GSK3b through a PKC-mediated
mechanism, which may in part be responsible for the stabilisation
and accumulation of b-catenin levels. b-catenin translocates to
the nucleus where it acts as a co-factor to TCF, to increase the
transcription of TCF target genes, including Fra1, Jun and Myc.
b-catenin also interacts with SF1, which together with other
DNA-binding proteins (including EGR1, JUN and ATF3) increases
transcription of Lhb, and possibly of Cga, Fshb and Gnrhr. In
addition, b-catenin may act as a co-factor to regulate members
of the FoxO family and the androgen receptor (AR). GSK3b may
target the activities of other transcription factors in gonadotropes,
Wnt signalling mediators in gonadotropes . S GARDNER and others 197Targeting Wnt signalling mediators by
non-FZD GPCRs
Anumber of non-FZDGPCRs have been shown to target
b-catenin/TCF activity in response to their cognate
ligands, including the prostanoid receptors (Fujino &
Regan 2001, Fujino et al. 2002), M1 muscarinic
acetylcholine receptor (Farias et al. 2004), lysopho-
sphatidic acid (LPA) receptor (Yang et al. 2005) and
thromboxane A2/TPa receptor (Yan & Tai 2006). The
first demonstration of non-FZD targeting of b-catenin/
TCF-dependent signalling was through the FPB prosta-
noid receptor (Fujino & Regan 2001). Stimulation of
FPB-expressing cells with prostaglandin F2a (PGF2a) led
to reorganisation of b-catenin, a decrease in phos-
phorylation of cytoplasmic b-catenin and activation of
b-catenin/TCF-dependent transcription. In addition to
these findings, it was demonstrated that activation of the
EP2 and EP4 prostanoid receptors by PGE2 promoted
b-catenin/TCF-dependent transcription (Fujino et al.
2002). In addition, the EP2 and EP4 receptors were
demonstrated to target Ser9 GSK3b phospho-inhibition
by a PKA-dependent mechanism (Fujino et al. 2002).
The M1 muscarinic acetylcholine receptor was demon-
strated to inhibit GSK3b activity, stabilise b-catenin levels
and induce the expression of the Wnt target genes en-1
and cycD1 resulting in the protection of neurons from
amyloid-b-peptide neurotoxicity in a rodent model of
Alzheimer’s disease (Farias et al. 2004). The LPA
receptor was demonstrated to target b-catenin to induce
colon cancer cell proliferation (Yang et al. 2005). LPA
was shown to promote the nuclear translocation of
b-catenin, activation of b-catenin/TCF-dependent tran-
scription, phospho-inhibition of GSK3b and activation
of b-catenin/TCF target genes. Furthermore, all these
LPA-induced events were apparently dependent on
conventional PKC activity (Yang et al. 2005). The
thromboxane A2/TPa receptor was demonstrated to
activate b-catenin/TCF-dependent transcription appa-
rently through the phospho-inhibition of GSK3b (Yan &
Tai 2006; Fig. 1).including CREB and NFAT, which may therefore be subject to an
additional level of regulation by GnRH, since GnRH inhibits
GSK3b activity. See text for details.The GnRH receptor targets GSK3b
phospho-inhibition and b-catenin/TCF
transcriptional activity
The above studies suggested that further cross-talk
between signalling mediators of the Wnt/b-catenin
pathway and those activated by GPCRs is likely. Indeed,
several recent studies have demonstrated that GnRH,
acting at theGnRH receptor, can targetmediators of the
Wnt/b-catenin signalling pathway in both a heter-
ologous HEK293 model cell line and the LbT2
gonadotrope cell line (Gardner et al. 2007, Salisbury
et al. 2007, 2008, 2009, Gardner & Pawson 2009).www.endocrinology-journals.orgThe initial studies reported GnRH-mediated nuclear
accumulation of b-catenin, activation of b-catenin/TCF-
dependent transcription (using a TCF-dependent luci-
ferase reporter plasmid) and theup-regulationof several
b-catenin/TCF target genes including Jun, Fra1 andMyc
(Gardner et al. 2007). In addition, it was demonstrated
that GnRH targets Ser9 GSK3b phospho-inhibition
(Gardner et al. 2007). As discussed above, the accumu-
lation of b-catenin in response to GnRH may be
independent of the Ser9 phospho-inhibition of GSK3b
since the Wnt pool of GSK3b is probably functionallyJournal of Molecular Endocrinology (2010) 44, 195–201
S GARDNER and others . Wnt signalling mediators in gonadotropes198distinct from the pool of GSK3b that GnRH targets. The
mechanism whereby GnRH targets b-catenin accumu-
lation and Ser9 GSK3b phospho-inhibition was shown to
be mediated via Gq/11 coupling, and is most likely PKC
dependent (Gardner et al. 2007). Furthermore, GnRH
does not signal through PI3K–Akt/PKB to target GSK3b
phospho-inhibition, as is the case in classical insulin
signalling, since pharmacological inhibition of PI3K
failed to block b-catenin/TCF transcriptional activity in
response to GnRH (Gardner et al. 2007).
Apart from its role as a TCF co-factor in the canonical
Wnt signalling pathway, b-catenin can function as a
co-factor to a number of other transcription factors
relevant to gonadotrope biology, including SF1 and JUN
(Angel et al. 1988, Desclozeaux et al. 2002, Shah et al. 2002,
Gummow et al. 2003, Mizusaki et al. 2003, Parakh et al.
2006). Thus, the ability of GnRH to stimulate the
expression of b-catenin/TCF target genes suggests that
SF1- and JUN-responsive genes may also be targets of
GnRH-dependent b-catenin/TCF transcriptional activity.
This is because functional cross-talk between SF1, JUN
and b-catenin/TCF signalling has been demonstrated in
several studies (Shah et al. 2002, Gummow et al. 2003,
Mizusaki et al. 2003, Veeman et al. 2003, Le Floch et al.
2005). Furthermore, b-catenin acts as a co-factor of SF1
through a direct interaction (Gummow et al. 2003,
Mizusaki et al. 2003, Parakh et al. 2006), while JUN can
interact co-operatively with TCF in the b-catenin/TCF
complex at JUN promoter sites (Nateri et al. 2005).Targeting b-catenin/TCF transcriptional
activity in gonadotropes
The ability of GnRH to stimulate the expression of
b-catenin/TCF target genes, and the finding that both
SF1- and JUN-responsive genes may also be targets of
GnRH-dependent b-catenin/TCF transcriptional
activity, has important implications for gonadotrope
function, including the expression of Lhb, Cga, Fshb and
Gnrhr genes. An important study highlighting the role
of b-catenin as a member of a transcription factor
complex that drives maximal activity of the Lhb
subunit promoter in response to GnRH was published
(Salisbury et al. 2007). This study by Nilson et al.
demonstrates the co-localisation of b-catenin with SF1
and EGR1 on the promoter of the Lhb subunit gene in
response to GnRH, and suggests that endogenous SF1
and b-catenin can physically associate in LbT2 cells
(Salisbury et al. 2007). A role for GnRH targeting of
b-catenin/TCF activity to regulate the expression of
JUN-responsive genes including Cga, Fshb and Gnrhr,
which additionally require SF1, is yet to be demon-
strated. What is clear though is that b-catenin has an
important role to play, and that it regulates gonado-
trope responsiveness to GnRH.Journal of Molecular Endocrinology (2010) 44, 195–201Concluding remarks and future direction
The ability of GnRH to impinge on the activity of Wnt
signalling mediators has several implications for further
understanding key processes in gonadotrope biology.
For example, CREB has a well-known role in regulating
Gnrhr expression by targeting CRE sites within theGnrhr
promoter in response to GnRH stimulation (Cheng &
Leung 2001, Maya-Nunez & Conn 2001). GSK3 has
been proposed as one of a number of kinases that
regulate CREB activity (Frame & Cohen 2001, Grimes &
Jope 2001, Doble & Woodgett 2003). Thus, by
promoting the Ser9 phospho-inhibition of GSK3b,
GnRH signal transduction may provide an additional
level of complexity in the regulation of CREB activity
and its ability to function optimally at the Gnrhr
promoter. GSK3 can also target the activity of the
Ca2C-sensitive transcription factor NFAT by function-
ing as a nuclear export kinase, thereby terminating
NFAT transcriptional activity (Crabtree & Olson 2002).
GnRH has been shown to mediate the derepression of
the Fshb gene in the aT3-1 gonadotrope cell line
through the activation of the Ca2C/CaN pathway
leading to NFAT-driven expression of Nur77 (Lim
et al. 2007). Furthermore, a recent study has reported
that GnRH-mediated Ca2C/NFAT signalling does not
act as the GnRH pulse frequency decoder in LbT2 cells
(Armstrong et al. 2009). It will be interesting to
determine if there is a role for GnRH-mediated
Ser9 phospho-inhibition of GSK3b in regulating NFAT
nuclear residency and how this impacts on gonado-
trope function with regard to these studies. As a multi-
functional kinase with a diverse array of proposed
targets, it is likely that many more roles for GSK3 in the
gonadotropes will emerge.
Additional roles for b-catenin are also likely, includ-
ing the regulation of androgen receptor (AR) activity.
As an AR co-factor, b-catenin functions to both inhibit
and stimulate AR target gene expression in a variety
of cell types and tissues (Chesire & Isaacs 2003,
Mulholland et al. 2005, Terry et al. 2006, Robinson
et al. 2008). Expression of Cga (a-polypeptide glyco-
protein hormones), Lhb and Fshb subunit gene is widely
reported to involve a component of androgen
regulation in gonadotropes; however, possible roles
for b-catenin in modulating AR activity at this level
(in response to GnRH) have not been reported yet
(Curtin et al. 2001, Jorgensen & Nilson 2001a,b, Curtin
et al. 2004, Spady et al. 2004, Thackray et al. 2006, Burger
et al. 2007, Thackray & Mellon 2008). Furthermore,
roles for FOXO transcription factors, which employ
b-catenin as a co-factor, have been proposed (Essers
et al. 2005, Malbon 2005, Hoogeboom et al. 2008, Jin
et al. 2008, Hoogeboom & Burgering 2009, Stavrou et al.
2009). Although clearly speculative, elucidating
potential roles for GSK3b and b-catenin wouldwww.endocrinology-journals.org
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regulation of gonadotropin subunit expression and
gonadotrope function.
In conclusion, this review has highlighted both
published and putative roles for mediators of the Wnt
signalling pathways in targeting important biological
processes in gonadotrope biology. We suggest that new
avenues of research will continue to emerge in order to
advance our understanding of the targeting of Wnt
signalling mediators by GnRH to in turn regulate
gonadotrope function. Indeed, such studies are already
well underway.Declaration of interest
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